Clinuvel Pharmaceuticals (ASX:CUV) is an Australian biopharmaceutical company that develops and commercialises novel phototherapeutic drugs to treat and protect people with genetic photosensitivity disorders. The company's flagship product, Scenesse®, is a prescription drug for the treatment of erythropoietic protoporphyria (EPP), a rare genetic disorder that causes severe pain and burning sensations in the skin when exposed to sunlight.